Treatment of recurrent aphthous stomatitis in immunocompromised patients. Systematic review
Keywords:
Recurrent aphthous stomatitis, treatment, therapy, immunocompromised patients, systematic review, vitamin B 12 and therapeutic use, thalidomide and therapeutic use, lasers semiconductor and therapeutic useAbstract
Background:Although recurrent aphthous stomatitis does not have a well-defined etiology due to it is a multicausal disease, it has been recognized that the interactions or the weakening of the immune system, contribute mainly to the magnitude of the process pathological. Treatment proposals in immune compromised patients are diverse and they usually focus on specific immunological alterations.
Objective:To evaluate the clinical effect of the proposed treatments for recurrent aphthous stomatitis in immunocompromised patients.
Methodology:The search was performed in the PubMed/Medline and Cochrane databases. Clinical trials were included that could have among their main response variables: Aphthous ulcer healing, healing time, recurrence and pain intensity and among the secondary variables: Adverse effects and symptoms. data extraction was done independently by the authors. The methodology was applied by Cochrane collaboration to assess the risk of bias in each of the studies.
Results:11 clinical trials (8 controlled) published between 1995 and 2020 and that provided the results of the efficacy of various therapeutic interventions: thalidomide (4), irsogladine (2), rebamipide (1), diode laser (1), Omega-3 capsules (1), vitamin B 12 (1), Complex B (1). Six of these studies included patients with the minor form of stomatitis recurrent aphthous. The follow-up period was between 14 and 360 days.
Conclusions:Thalidomide may be effective in relieving symptoms, healing and remission of the lesions, the laser diode and vitamin B12 in the decrease of the intensity of the pain.
Downloads
References
1. Rodríguez-Archilla A, Raissouni T. Estudio clínico de 200 pacientes con estomatitis aftosa recurrente. Gac Med Mex. [Internet]. 2018 [citado 10 Ene 2021];154(2):165-71. Disponible en: Disponible en: https://www.gacetamedicademexico.com/files/gmm_154_2_165-171.pdf
2. Queiroz SIML, Silva MVA, Medeiros AMC, Oliveira PT, Gurgel BCV, Silveira EJD. Recurrent aphthous ulceration: an epidemiological study of etiological factors, treatment and differential diagnosis. An Bras Dermatol [Internet]. 2018 [cited 2021 Jan 10];93(3):341-6. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001102/pdf/abd-93-03-0341.pdf
3. Edgar NR, Saleh D, Miller RA. Recurrent Aphthous Stomatitis: A Review. J Clin Aesthet Dermatol [Internet]. 2017 [cited 2021 Jan 10];10(3):26-36. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367879/pdf/jcad_10_3_26.pdf
4. Ruan HH, Li GY, Duan N, Jiang HL, Fu YF, Song YF, et al. Frequencies of abnormal humoral and cellular immune component levels in peripheral blood of patients with recurrent aphthous ulceration. J Dent Sci. [Internet]. 2018 [cited 2021 Jan 10];13(2):124-130. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388805/pdf/main.pdf
5. Saikaly SK, Saikaly TS, Saikaly LE. Recurrent aphthous ulceration: a review of potential causes and novel treatments. J Dermatolog Treat [Internet]. 2018 [cited 2021 Sep 18];29(6):542-552. Available from: Available from: https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1422079
6. Grimaux X, Leducq S, Goupille P, Aubourg A, Miquelestorena-Standley E, Samimi M. Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease. Ann Dermatol Venereol [Internet]. 2018 Nov [cited 2021 Jan 15];145(11):676-682. Available from: Available from: https://www.sciencedirect.com/science/article/abs/pii/S015196381830499X?via%3Dihub
7. Tekcan A, Yigit S, Nursal AF, Tumer MK, Yerliyurt K, Kuruca N. Analysis Of İnterleukin-1 Receptor Antagonist Variable Number Tandem Repeat Variant in Recurrent Aphthous Stomatitis. Endocr Metab Immune Disord Drug Targets [Internet]. 2021 [cited 2021 Sep 18];21(1):139-44. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/32282310/
8. Ding X, Xu F, Zhang X. Clinical therapeutic effects of topical agents in adult patients with human immunodeficiency virus-related oral mucosa ulcers. Medicine (Baltimore) [Internet]. 2021 [cited 2021 Sep 18];100(6). Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886410/pdf/medi-100-e23626.pdf
9. Samantha H, Shokrollah E. HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation. Front Immunol [Internet]. 2017 [cited 2021 Jan 10];8(241). Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339276/pdf/fimmu-08-00241.pdf
10. Nur'aeny N, Gurnida DA, Suwarsa O, Sufiawati I. The Impact of DNA Methylation on IL6 mRNA Levels in Hematinic Deficiency and Atopy-Associated Recurrent Aphthous Stomatitis Patients. Int J Dent [Internet]. 2021 [cited 2021 Sep 18];2021:1-11. Available from: Available from: https://downloads.hindawi.com/journals/ijd/2021/5560695.pdf
11. Yang Z, Cui Q, An R, Wang J, Song X, Shen Y, et al. Comparison of microbiomes in ulcerative and normal mucosa of recurrent aphthous stomatitis (RAS)-affected patients. BMC Oral Health [Internet]. 2020 [cited 2021 Jan 10];20(1):128. Available from: Available from: https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-020-01115-5
12. Cabras M, Carrozzo M, Gambino A, et al. Value of colchicine as treatment for recurrent oral ulcers: A systematic review. J Oral Pathol Med [Internet]. 2020 [cited 2021 Jan 10];49(8):731-740. Available from: Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jop.13020
13. Kuteyi T, Okwundu CI. Topical treatments for HIV-related oral ulcers. Cochrane Database Syst Rev [Internet]. 2012 [2021 Jan 10];(1). Available from: Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007975.pub2/full
14. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis [Internet].1995 Feb [cited 2021 Jan 10];20(2):250-4. Available from: Available from: https://academic.oup.com/cid/article-abstract/20/2/250/376713?redirectedFrom=fulltext
15. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. [Internet].1997 [cited 2021 Jan 10];336(21):1487-93. Available from: Available from: https://www.nejm.org/doi/10.1056/NEJM199705223362103?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0www.ncbi.nlm.nih.gov
16. Jacobson JM, Greenspan JS, Spritzler J, Fox L, Fahey JL, Jackson JB. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis. [Internet]. 2001 [cited 2021 Jan 10];183(2):343-346. Available from: Available from: https://academic.oup.com/jid/article/183/2/343/850304
17. Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. Clinics (Sao Paulo). [Internet]. 2009 [cited 2021 Jan 10];64(3):193-8. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666466/pdf/cln64_3p0193.pdf
18. Nanke Y, Kamatani N, Okamoto T, Ogiuchi H, Kotake S. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an open-label, single-centre study. Drugs R D. [Internet]. 2008 [cited 2021 Jan 10];9(6):455-9. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/18989994/
19. Hayashi N, George J, Shiroeda H, Saito T, Toshikuni N, Tsuchishima M, et al. Irsogladine maleate for the treatment of recurrent aphthous stomatitis in hepatitis C virus patients on pegylated-interferon and ribavirin: a pilot study. J Gastroenterol Hepatol [Internet]. 2013 Jun [cited 2021 Jan 10];28(6):1015-8. Available from: Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12137
20. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D [Internet]. 2003 [cited 2021 Jan 10];4(1):19-28. Available from: Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12137
21. Huo X, Han N, Liu L. Effect of different treatments on recurrent aphthous stomatitis: laser versus medication. Lasers Med Sci [Internet]. 2021 [cited 2021 Sep 18];36:1095-1100. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/33140267/
22. Hadian Z, Moghadamnia AA, Kazemi S, Shirzad A. Effect of Omega-3 on Recurrent Aphthous Stomatitis and Improvement Quality of Life. Int J Dent [Internet]. 2021 [cited 2021 Sep 18];2021. Available from: Available from: https://downloads.hindawi.com/journals/ijd/2021/6617575.pdf
23. Golestannejad Z, Ghalayani P, Mojthaedi N, Foroughi A. The effectiveness of submucosal injection bioactive vitamine b12 in comparision to triancinolone in pain and frecuency of apthous ulcer. Ann Dent Spec [Internet]. 2017 [cited 2021 Jan 10];5(3):122-125. Available from: Available from: https://annalsofdentalspecialty.net.in/storage/models/article/IEpxGJAby2yL8vE6iP8V13lM8Y2XUZEKpuvp7BT316R8D1rgodDjQGGIdewo/9-the-effectiveness-of-submucosal-injection-bioactive-vitamin-b12-in-comparison-to-triaminolone-in.pdf
24. Rasi A, Zamanian A, Mehran G, Ezati A, Rastin V, Karimi S. Comparing the Effect of Injectable Vitamin B With Conventional Oral Treatment on Aphthous Stomatitis. J Skin Stem Cell [Internet]. 2018 [cited 2021 Jan 10];5(1-2):e69052. Available from: Available from: https://sites.kowsarpub.com/jssc/articles/69052.html
25. Taleb R, Hafez B, El Kassir N, El Achkar H, Mourad M. Role of vitamin B12 in treating recurrent aphthous stomatitis: A review. Int J Vitam Nutr Res [Internet]. 2020 [cited 2021 Jul 18]:1-8. Available from: Available from: https://econtent.hogrefe.com/doi/pdf/10.1024/0300-9831/a000684
Downloads
Published
How to Cite
Issue
Section
License
La revista GME tiene Acceso Abierto (Open Access) a su contenido bajo las premisas de que el libre acceso mejora el sistema de comunicación científica, lo cual elimina cualquier barrera que impida el acceso a la información y de que el mismo autor es el máximo beneficiario de este movimiento, al proporcionarle ventajas tanto en su aspecto económico, científico, como en servicios de valor añadido.
Los autores conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra; podrán establecer acuerdos adicionales para la distribución no exclusiva de la versión de la obra publicada en la revista, con el reconocimiento de haber sido publicado primero en esta revista.
Todo el contenido de esta revista se encuentra en Acceso Abierto, distribuido según los términos de la licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
Download here;
